

GMP MANUAL Contents

- 1 **Pharmaceutical Quality System (PQS)****
- 1.A **Preface****
- 1.B **The road to a Pharmaceutical Quality System****
- 1.C **Introduction to the PQS****
- 1.C.1 General requirements
- 1.C.2 Documentation
- 1.D **Main elements of a PQS****
- 1.D.1 Management responsibility
- 1.D.2 Resource management
- 1.D.3 Manufacturing operations
- 1.D.4 Evaluation activities
- 1.E **Essentials of a PQS****
- 1.E.1 Principles of a process
- 1.E.2 Process mapping
- 1.E.3 Responsibilities
- 1.E.4 Key Performance Indicators (KPIs)
- 1.F **Practical implementation of a PQS****
- 1.F.1 Assistance for implementation
- 1.F.2 Organizational aspects
- 1.F.3 Process of developing documents
- 1.F.4 Document hierarchy
- 1.G **Structure of a PQS quality manual – example****
- 1.H **Correlation between GMP requirements (WHO) and ISO 9001:2000****
- 1.I **References****
- 2 **Personnel****
- 2.A **Place of work and job descriptions****
- 2.B **Requirements of the personnel****
- 2.B.1 Qualification requirements
- 2.B.2 Health requirements

- 2.C Training**
- 2.C.1 Purpose of training
 - 2.C.2 Responsibility for training
 - 2.C.3 Requirements profiles/learning objectives
 - 2.C.4 Training contents and target groups
 - 2.C.5 Training planning
 - 2.C.6 Carrying out
 - 2.C.7 Reviewing the training and the training system
 - 2.C.8 Documentation

- 2.D Function owners subject to public law**
- 2.D.1 Qualified Person (QP)
 - 2.D.2 Head of Production
 - 2.D.3 Head of Quality Control
 - 2.D.4 Qualified Person in Accordance with Article 103 of Guideline 2001/83/EC
 - 2.D.5 Scientific Service in Charge of Information
 - 2.D.6 Medical sales representatives

3 Premises

- 3.A Official Requirements**
- 3.A.1 Location, connection to other rooms
 - 3.A.2 Size, area, height
 - 3.A.3 Installation and supply of utilities
 - 3.A.4 Lighting, ventilation, air-conditioning
 - 3.A.5 Hygienic construction
 - 3.A.6 Room book and layout

- 3.B Material flow, personnel flow and layout**
- 3.B.1 Material flow
 - 3.B.2 Personnel flow
 - 3.B.3 Layout
 - 3.B.4 Design concepts in FDA's Sterile Drug Products Produced by Aseptic Processing guideline

- 3.C Room classes**
- 3.C.1 General GMP Requirements for Premises
 - 3.C.2 GMP Requirements for Cleanrooms: Air Cleanliness Grades
 - 3.C.3 Corresponding FDA Determinations
 - 3.C.4 GMP Requirements for Premises
 - 3.C.5 Room-specific Allocation of Air Cleanliness Stipulations
 - 3.C.6 Cleanliness Zoning Concepts
 - 3.C.7 Converting GMP Stipulations into Reality

- 3.D Construction elements**
 - 3.D.1 Walls
 - 3.D.2 Doors and windows
 - 3.D.3 Floors
 - 3.D.4 Ceilings
- 3.E Barrier systems and isolators**
 - 3.E.1 Protection concepts for maximized sterility assurance
 - 3.E.2 Pharmaceutical isolator technology
 - 3.E.3 Restricted access barrier systems (RABS technology)
 - 3.E.4 Application options for RABS and isolators
- 3.F Building services**
 - 3.F.1 Basic requirements for installation
 - 3.F.2 Heating
 - 3.F.3 Sanitary plumbing and sewage
 - 3.F.4 Electrical installations incl. IT-management and control systems
 - 3.F.5 Qualification
- 3.G Heating Ventilation Air Conditioning (HVAC)**
 - 3.G.1 Introduction
 - 3.G.2 Room ventilation systems
 - 3.G.3 Filters
 - 3.G.4 Principles for the design and planning of air conditioning ventilation systems
 - 3.G.5 Design criteria for the ventilation of premises
 - 3.G.6 Maintenance of air ventilation systems
- 3.H Process Gases**
 - 3.H.1 Quality Requirements
 - 3.H.2 Generation, Storage and Distribution
 - 3.H.3 System design
 - 3.H.4 Qualification and monitoring
- 3.I Qualification of premises and air-conditioning systems**
 - 3.I.1 Objectives of qualification
 - 3.I.2 Regulatory and normative fundamentals of qualification
 - 3.I.3 Project development and qualification
 - 3.I.4 Qualification Master Plan
 - 3.I.5 Qualification Plans and Qualification Reports
 - 3.I.6 Qualification checklists
 - 3.I.7 Requirements for measurement and test reports
 - 3.I.8 Requalification
- 3.J Monitoring of HVAC systems**
 - 3.J.1 Objectives of process monitoring
 - 3.J.2 Data management stipulations
 - 3.J.3 Air cleanliness and other room air data

- 3.J.4 Risks of microbiological monitoring
- 3.J.5 Alarm and action limits
- 3.J.6 Operation and maintenance

3.K References

4 Facilities and Equipment

4.A Introduction

4.B Mechanical components

- 4.B.1 Construction and installation materials
- 4.B.2 GMP-compliant design characteristics
- 4.B.3 Electrical and pneumatic components

4.C Control

4.D Facility concepts

- 4.D.1 CIP (Cleaning in Place)
- 4.D.2 Isolator technology
- 4.D.3 Connected facilities

4.E Examples of facility qualification,

- 4.E.1 Design qualification
- 4.E.2 Installation qualification
- 4.E.3 Operational qualification

4.F Technical documentation

- 4.F.1 Necessity
- 4.F.2 Scope and content
- 4.F.3 Administration of the technical documentation
- 4.F.4 Log book

4.G Calibration

- 4.G.1 Definitions
- 4.G.2 Procedure
- 4.G.3 Documentation
- 4.G.4 Administration of scheduled calibration dates/ times

4.H Maintenance

- 4.H.1 Types of maintenance
- 4.H.2 GMP-conforming maintenance
- 4.H.3 Systems for maintenance

4.I CIP (Cleaning in Place)

- 4.I.1 Introduction
- 4.I.2 CIP systems
- 4.I.3 GMP-conforming design of CIP facilities
- 4.I.4 Nozzle heads for container cleaning

- 4.I.5 Measuring technology
- 4.I.6 Realisation of cleaning systems
- 4.J Containment (personnel protection) in solids handling**
 - 4.J.1 Significance
 - 4.J.2 Definition of terms
 - 4.J.3 Containment grades of products
 - 4.J.4 Measurement of the residue limits (OEL)
 - 4.J.5 Example of containment facility planning
 - 4.J.6 Containment weak points
 - 4.J.7 Containment systems for filling and emptying drums
 - 4.J.8 Container systems
 - 4.J.9 Filter systems
 - 4.J.10 Sampling
 - 4.J.11 Containment on equipment
- 4.K Process control systems**
 - 4.K.1 Definitions
 - 4.K.2 Features of process control systems
 - 4.K.3 How to use process control systems
 - 4.K.4 Carrying out a process control system project
 - 4.K.5 Qualification of process control systems
- 4.L Hygienic (sanitary) design when using solids**
 - 4.L.1 Introduction
 - 4.L.2 Surfaces
 - 4.L.3 Material: stainless steel
 - 4.L.4 Connections
 - 4.L.5 Hoists and roller conveyors
 - 4.L.6 Pneumatic conveyor system
 - 4.L.7 Dosing systems
 - 4.L.8 Platforms and stands
 - 4.L.9 Clean room installations
- 5 Pharmaceutical Water**
 - 5.A Water types**
 - 5.A.1 Potable water
 - 5.A.2 Purified water
 - 5.A.3 Highly purified water
 - 5.A.4 Water for injection
 - 5.B Generation of pharmaceutical water**
 - 5.B.1 Purified water (PW)
 - 5.B.2 Water for injection (WFI)
 - 5.B.3 Purification of pharmaceutical water treatment systems

5.C Distribution and storage of pharmaceutical water

- 5.C.1 Loop
- 5.C.2 Fixtures
- 5.C.3 Measuring technique
- 5.C.4 Formation of biofilms
- 5.C.5 Rouging
- 5.C.6 Buffering of ultra pure water
- 5.C.7 Loop with subloops

5.D Qualification of water supplies

- 5.D.1 Introduction
- 5.D.2 Risk analysis
- 5.D.3 Design qualification
- 5.D.4 Installation qualification
- 5.D.5 Operational qualification (OQ)
- 5.D.6 Transfer to the user
- 5.D.7 Process validation/performance qualification (PQ)
- 5.D.8 Qualification report

5.E Operation of water supplies

- 5.E.1 Procedures to reduce microbial counts
- 5.E.2 Maintenance of a water supply
- 5.E.3 Calibration of measuring systems
- 5.E.4 Change control
- 5.E.5 Requalification
- 5.E.6 Decommissioning/uninstalling

5.F Pure steam systems

- 5.F.1 Physical principles
- 5.F.2 Quality requirements for pure steam
- 5.F.3 Pure steam generation
- 5.F.4 Pure steam distribution system

6 Qualification**6.A Official requirements**

- 6.A.1 Legal aspects of qualification
- 6.A.2 Documentation of the qualification
- 6.A.3 Design Qualification (DQ)
- 6.A.4 Installation Qualification (IQ)
- 6.A.5 Operational Qualification (OQ)
- 6.A.6 Performance Qualification (PQ)
- 6.A.7 Qualification of established facilities
- 6.A.8 Requalification

- 6.B Preparation of the qualification**
 - 6.B.1 Commissioning
 - 6.B.2 Sequence
 - 6.B.3 Qualification team
 - 6.B.4 Responsibilities
 - 6.B.5 Qualification by external service providers
 - 6.B.6 Risk analysis
- 6.C Qualification documentation**
 - 6.C.1 Qualification master plan
 - 6.C.2 Qualification plan
 - 6.C.3 Qualification report
 - 6.C.4 Labeling of the qualification status
 - 6.C.5 SOP – “Qualification of facilities and equipment”
- 6.D Design qualification (DQ)**
 - 6.D.1 User requirements (user specifications)
 - 6.D.2 Technical specification
- 6.E Installation qualification (IQ)**
 - 6.E.1 Examples of IQ plans
 - 6.E.2 Example: Fluid bed equipment
- 6.F Operational qualification(OQ)**
 - 6.F.1 Examples of OQ plans
 - 6.F.2 Example: Fluid bed dryer
- 6.G Performance qualification (PQ)**
- 6.H Special cases of qualification**
 - 6.H.1 Retrospective qualification
 - 6.H.2 Requalification
 - 6.H.3 Content of a review
 - 6.H.4 Maintenance of the qualified status
 - 6.H.5 Qualification of simple equipment

7 Process Validation

- 7.A Official requirements**
 - 7.A.1 Regulative aspects
 - 7.A.2 Principles of process validation
 - 7.A.3 Types of process validation
 - 7.A.4 Maintaining the validated status
 - 7.A.5 Documentation of process validation
- 7.B Validation – a key element of quality management**
 - 7.B.1 What is the significance of validation?
 - 7.B.2 How is validation defined?

- 7.B.3 Who must perform validation?
- 7.B.4 What faults can occur during validation?
- 7.B.5 What are the benefits of validation?
- 7.B.6 Current trends in process validation
- 7.B.7 Process validation from the viewpoint of the FDA

7.C Validation planning and procedure

- 7.C.1 Process validation approaches
- 7.C.2 Prerequisites and responsibilities
- 7.C.3 Scope of Validation

7.D Validation documentation

- 7.D.1 Structure and archiving
- 7.D.2 Validation master plan
- 7.D.3 Validation protocol
- 7.D.4 Validation report
- 7.D.5 Documentation examples

7.E Process Validation and Product Lifecycle

- 7.E.1 Quality by Design
- 7.E.2 Process Analytical Technology (PAT)
- 7.E.3 Maintaining the validated state
- 7.E.4 Process validation as a three-stage life cycle model

7.F References

8 Cleaning Validation

8.A Official requirements

8.B How to validate cleaning procedures

- 8.B.1 Optimization of cleaning procedures
- 8.B.2 Compilation of cleaning instructions
- 8.B.3 Validating manual and automated cleaning procedures

8.C Cleaning validation master plan

8.D Establishing the scope of validation

- 8.D.1 Bracketing: determination of critical substances
- 8.D.2 Matrixing: determination of equipment-specific validation protocols

8.E Acceptance criteria and limit calculation

- 8.E.1 Calculation of active pharmaceutical ingredient residues
- 8.E.2 Calculation of cleansing agent residues
- 8.E.3 Determination of the microbial status

8.F Sampling procedures

- 8.F.1 Swab test
- 8.F.2 Rinse test

- 8.F.3 Other procedures
- 8.F.4 Selection of the appropriate sampling procedure
- 8.F.5 Microbiological testing of surfaces
- 8.G Analytical procedures**
- 8.G.1 Requirements for method validation
- 8.G.2 Selection of the appropriate analytical procedure
- 8.H Documentation**
- 8.H.1 Validation protocol
- 8.H.2 Validation report
- 8.H.3 Other documents
- 8.I Maintenance of the validated status**
- 8.I.1 Changes and deviations
- 8.I.2 Change control
- 8.I.3 Revalidation
- 8.I.4 New products and equipment
- 8.I.5 Deviations
- 8.J Cleaning validation documentation (example)**
- 8.K References**
- 9 Computer System Validation**
- 9.A Introduction and terminology**
- 9.B Legal aspects**
- 9.B.1 Europe
- 9.B.2 USA
- 9.B.3 PIC/S
- 9.B.4 Electronic signatures and electronic records
- 9.B.5 ISPE GAMP® 5 – Good Automated Manufacturing Practice
- 9.C System life cycle**
- 9.C.1 The “V model”
- 9.C.2 Software development
- 9.C.3 Configuration and customisation
- 9.D System classification and risk management**
- 9.D.1 System classification according to ISPE GAMP®5
- 9.D.2 Risk management
- 9.E Validation of computerised systems**
- 9.E.1 Validation organisation
- 9.E.2 Validation plan
- 9.E.3 Specifications (user requirements/technical specification)
- 9.E.4 Unit, integration, system and acceptance tests

- 9.E.5 Validation report
- 9.E.6 Data migration and start-up
- 9.E.7 Examples
- 9.E.8 Retrospective validation
- 9.F Operation of computerised systems**
 - 9.F.1 System description
 - 9.F.2 User training
 - 9.F.3 Standard operating procedures (SOPs)
 - 9.F.4 Access and security
 - 9.F.5 Data backup and archiving
 - 9.F.6 Contingency plans
 - 9.F.7 Change management and error reporting
 - 9.F.8 Periodic review
 - 9.F.9 Retirement of computerised systems
- 9.G External service providers**
 - 9.G.1 Relocation of activities
 - 9.G.2 Service level agreement
 - 9.G.3 Auditing of suppliers and service providers
- 9.H References**

10 Considerations on Risk Management

- 10.A Introduction and Principles**
 - 10.A.1 Advantages of Risk Management
 - 10.A.2 Considerations on the Risk-Based Approach
 - 10.A.3 Regulatory Environment
 - 10.A.4 Objectives
 - 10.A.5 Science-Based Approach
 - 10.A.6 Summary
- 10.B Basic Consideration on Implementing Risk Management Into a Process**
 - 10.B.1 Areas of Hazards
 - 10.B.2 Prerequisites
 - 10.B.3 Use of Knowledge and Experience
 - 10.B.4 Consideration on Manual Operations
 - 10.B.5 Elements of Risk Management
 - 10.B.6 Implementation of a Risk Management Process
 - 10.B.7 Commitment of Management
 - 10.B.8 Project Team
 - 10.B.9 Analysis of Existing Risk Management Approaches
 - 10.B.10 Standardization of Methods and Tools
 - 10.B.11 Considerations on Risk Based Behavior
 - 10.B.12 Additional Training Required?

10.C	Details on Using Risk Management Principles as Behavior
10.C.1	Application to the QM System
10.C.2	The Team
10.C.3	Assessment Criteria
10.C.4	Procedure to Determine Conclusions
10.C.5	Evaluation on Individual Topics (Detailed Evaluation) Using Risk Management
10.C.6	Example on Process Validation
10.D	Methodologies to be Used to Facilitate Risk Management
10.E	Using Process Mapping
10.F	Using a Fishbone Diagram
10.F.1	Create a Fish Bone Diagram
10.F.2	Advantages and Disadvantages
10.G	Informal Use of Risk Management
10.H	Fault Tree Analysis (FTA)
10.H.1	Basic Principles
10.H.2	Objective: What a FTA Can Do and Where to Use It
10.H.3	How to Run the Process of a FTA
10.H.4	Prerequisites for an FTA
10.H.5	Execution of an FTA
10.H.6	Advantages and Disadvantages of an FTA
10.I	Failure Mode Effects Analysis (FMEA)
10.I.1	Objectives and Areas of Application
10.I.2	General Items on the FMEA Process
10.I.3	Implementation of FMEA in a Project
10.I.4	Advantages and Disadvantages of an FMEA
10.I.5	Application Example of a Modified FMEA
10.J	Hazard Analysis of Critical Control Points (HACCP)
10.J.1	Prerequisite and Result to be Expected
10.J.2	Advantages and Disadvantages
10.J.3	Application Example
10.K	Conclusion
11	Production
11.A	Sanitation
11.A.1	Organisational prerequisites
11.A.2	Sources of contamination
11.A.3	Responsibilities and implementation

- 11.B Personnel hygiene**
 - 11.B.1 Clothing
 - 11.B.2 Code of Conduct
 - 11.B.3 Hand disinfection
 - 11.B.4 Health requirements
 - 11.B.5 Training
- 11.C Production hygiene**
 - 11.C.1 Sources of contamination
 - 11.C.2 Cleaning
 - 11.C.3 Disinfection
- 11.D Sanitation programme**
 - 11.D.1 Organisation of room cleaning
 - 11.D.2 Documentation
- 11.E Environmental monitoring**
 - 11.E.1 General
 - 11.E.2 Sampling plan
 - 11.E.3 Establishment of limits and frequencies
 - 11.E.4 Methods
 - 11.E.5 Investigation areas
 - 11.E.6 Evaluation
- 11.F GMP in the production process**
- 11.G Weigh-in**
 - 11.G.1 Legal requirements
 - 11.G.2 Weigh-in principles
 - 11.G.3 Weigh-in procedure
 - 11.G.4 Documentation
- 11.H Identification**
 - 11.H.1 Handling of labels
 - 11.H.2 Labelling of starting materials
 - 11.H.3 Labelling of equipment and containers
 - 11.H.4 Labelling of rooms
- 11.I In-process control**
 - 11.I.1 Objectives
 - 11.I.2 Organisation and responsibilities
 - 11.I.3 Carrying out
 - 11.I.4 Documentation and evaluation of data
- 11.J Prevention of cross-contamination**
 - 11.J.1 Causes of cross-contamination
 - 11.J.2 Measures to prevent cross-contamination
 - 11.J.3 Manufacture of critical products

11.K Deviations

- 11.K.1 Definition
- 11.K.2 Procedure
- 11.K.3 Responsibilities
- 11.K.4 Measures
- 11.K.5 Failure investigation report
- 11.K.6 Evaluation of measures
- 11.K.7 SOP “deviations” – (example)
- 11.K.8 Check-list for deviation handling

11.L Reworking

- 11.L.1 Definitions
- 11.L.2 Procedure
- 11.L.3 Rework/Reprocessing of rejected products
- 11.L.4 Rework of returned products
- 11.L.5 Rework of products that have not been rejected

11.M Warehouse and logistics

- 11.M.1 Regulatory requirements
- 11.M.2 Stock management system
- 11.M.3 Responsibilities
- 11.M.4 Personnel
- 11.M.5 Storage areas
- 11.M.6 Storage conditions
- 11.M.7 Sanitation and pest control
- 11.M.8 Material Flow
- 11.M.9 Process Flow

11.N Transportation

- 11.N.1 Requirements for logistic service providers
- 11.N.2 Transportation challenges and monitoring devices
- 11.N.3 Cool/Cold Chain Distribution
- 11.N.4 Temperature Profiles
- 11.N.5 Transportation Risks

11.O References**12 Sterile Production****12.A Introduction**

- 12.A.1 Manufacturing of terminally sterilised products
- 12.A.2 Aseptic processing
- 12.A.3 Sterilisation procedures
- 12.A.4 GMP regulations, standards and guidelines

- 12.B Air Lock Concepts**
 - 12.B.1 Personnel locks in the clean area
 - 12.B.2 Material locks
- 12.C Manufacture of terminally sterilised products**
 - 12.C.1 Introduction
 - 12.C.2 Manufacturing a batch
 - 12.C.3 Washing processes
 - 12.C.4 Filling
 - 12.C.5 Validation
- 12.D Sterilisation processes**
 - 12.D.1 Introduction
 - 12.D.2 Normative background of sterilisation
 - 12.D.3 Sterilisation methods
 - 12.D.4 Steam sterilisation
 - 12.D.5 Dry heat sterilisation
 - 12.D.6 Radiation sterilisation
- 12.E Aseptic processing**
 - 12.E.1 Room requirements
 - 12.E.2 Monitoring
 - 12.E.3 Personnel
 - 12.E.4 Sterile filtration
 - 12.E.5 Validating aseptic processing (media fill)
- 12.F Freeze-drying**
 - 12.F.1 The concept of freeze-drying
 - 12.F.2 Freeze dryer design
 - 12.F.3 Process monitoring and control
 - 12.F.4 Qualification and process validation in freeze-drying
- 12.G Testing for Sterility**
 - 12.G.1 Introduction
 - 12.G.2 Parametric release
 - 12.G.3 Sterility Test
- 12.H Testing for Endotoxins**
 - 12.H.1 Introduction
 - 12.H.2 Methods for detection of endotoxins
 - 12.H.3 Tests According to Pharmacopeia
 - 12.H.4 Action Limits
 - 12.H.5 Gel-Clot Test
 - 12.H.6 Photometric Methods
 - 12.H.7 Elimination of Interfering Substances
 - 12.H.8 Out of Specification (OOS)

12.I Testing for Leakage and for Particles

- 12.I.1 Testing for Leakage
- 12.I.2 Testing for Particles
- 12.I.3 Operating Procedure

12.J Microbiological monitoring

- 12.J.1 Introduction
- 12.J.2 Sources of contamination
- 12.J.3 Room classification
- 12.J.4 Monitoring program
- 12.J.5 Level
- 12.J.6 Methods and equipment
- 12.J.7 Sampling
- 12.J.8 Measures if levels are exceeded
- 12.J.9 Organism identification

12.K References**13 Packaging****13.A Packaging material**

- 13.A.1 Responsibilities
- 13.A.2 Contents
- 13.A.3 Materials
- 13.A.4 Protection against counterfeit medicinal products
- 13.A.5 Packaging material testing

13.B Packaging process

- 13.B.1 Allocation of packaging material
- 13.B.2 Line clearance
- 13.B.3 Labelling
- 13.B.4 Control functions
- 13.B.5 Release for production
- 13.B.6 In-process controls
- 13.B.7 Cleaning primary containers
- 13.B.8 Labelling
- 13.B.9 Variable data
- 13.B.10 Imprints
- 13.B.11 Reconciliation
- 13.B.12 Safety features
- 13.B.13 Completion of a packaging process

13.C Qualification of a packaging line

- 13.C.1 Master qualification plan
- 13.C.2 Design qualification (DQ)
- 13.C.3 Installation qualification (IQ)

- 13.C.4 Operational qualification (OQ)
- 13.C.5 Performance qualification (PQ)

14 Laboratory Controls

14.A Sampling

- 14.A.1 Requirements
- 14.A.2 Sampling plan (instructions)
- 14.A.3 Notes for the sampling process

14.B Reagents

- 14.B.1 Labeling
- 14.B.2 Usage and stability
- 14.B.3 Documentation

14.C Standards and reference substances

- 14.C.1 Definition of different standards and their areas of use
- 14.C.2 Handling, storage and stability

14.D Qualifying laboratory instruments

- 14.D.1 Qualification protocols and reports
- 14.D.2 System suitability test (SST)

14.E Calibration in the lab

- 14.E.1 Definitions
- 14.E.2 Calibration instructions and record
- 14.E.3 Examples
- 14.E.4 Decision

14.F Validation of analytical methods

- 14.F.1 Principles
- 14.F.2 Definitions of the parameters
- 14.F.3 Documentation
- 14.F.4 Revalidation

14.G Stability testing

- 14.G.1 ICH guidelines for stability tests
- 14.G.2 Storage and storage conditions
- 14.G.3 Analyses
- 14.G.4 Reduction of the study design
- 14.G.5 Stability testing in the marketing phase
- 14.G.6 Defining the retest period for an active pharmaceutical ingredient and the shelf life for a drug product through evaluation of stability data (ICH Q1E)
- 14.G.7 Decision tree for data evaluation for retest period or for APIs or drug products (excluding frozen products)
- 14.G.8 Procedure for statistical analysis
- 14.G.9 Examples of the statistical evaluation of stability data

- 14.H Out-of-specification results**
 - 14.H.1 Significance
 - 14.H.2 Definitions
 - 14.H.3 FDA OOS Guidance
 - 14.H.4 Example for handling of an OOS result
 - 14.H.5 Trend tracking
- 14.I Raw data documentation**
 - 14.I.1 Principles
 - 14.I.2 Single sheet documentation system
- 14.J Batch release**
 - 14.J.1 Certification by a Qualified Person and release in accordance with EC GMP Guidelines
 - 14.J.2 Responsibility for issuing the release
 - 14.J.3 Publication of release
 - 14.J.4 Release procedures in practice
- 14.K Microbiological testing**
 - 14.K.1 Total microbial count
 - 14.K.2 Specified microorganisms
 - 14.K.3 Testing frequencies
 - 14.K.4 Miscellaneous tests
- 14.L Pharmacopoeias**
 - 14.L.1 Structure of Pharmacopoeias
 - 14.L.2 General considerations
 - 14.L.3 Development of Monographs
 - 14.L.4 European Pharmacopoeia (Ph Eur)
 - 14.L.5 British Pharmacopoeia (BP)
 - 14.L.6 United States Pharmacopoeia (USP)
 - 14.L.7 Japanese Pharmacopoeia (JP)
 - 14.L.8 International Pharmacopoeia (Ph Int)
 - 14.L.9 Harmonization
- 14.M References**
- 15 Documentation**
 - 15.A Official Requirements**
 - 15.A.1 Basic Principles of Documentation
 - 15.A.2 GMP-relevant Documents
 - 15.A.3 Requirements of the US GMP Regulations
 - 15.A.4 Document Management System
 - 15.A.5 Creating Documents
 - 15.A.6 Controlling and monitoring documents

- 15.B GMP-conforming documentation**
 - 15.B.1 Handwritten entries
 - 15.B.2 Archiving
 - 15.B.3 Master-SOP – “GMP-conforming documentation”
- 15.C Batch documentation**
 - 15.C.1 Manufacturing instructions/record
 - 15.C.2 Packaging instruction and batch packaging record
 - 15.C.3 Electronic batch recording
 - 15.C.4 Testing procedures and test protocol
 - 15.C.5 Batch record review
- 15.D Standard operating procedures (SOPs)**
 - 15.D.1 Compilation
 - 15.D.2 Approval and implementation
 - 15.D.3 Training
 - 15.D.4 Usage
 - 15.D.5 Review
 - 15.D.6 Changes
 - 15.D.7 Withdrawing an operating procedure
 - 15.D.8 Administration
 - 15.D.9 Archiving
 - 15.D.10 Example of an SOP “Compilation and administration of operating procedures”
- 15.E Site Master File**
 - 15.E.1 Introduction
 - 15.E.2 History
 - 15.E.3 Focus of recent update (PE 008-4)
 - 15.E.4 Regulatory requirements
 - 15.E.5 Guidelines for structure, contents and extent
- 15.F Annual product review / Product quality review**
 - 15.F.1 Documents required for an annual product review
 - 15.F.2 Annual product review report
 - 15.F.3 Collaboration with a contract manufacturer
 - 15.F.4 Example: annual product review
 - 15.F.5 Master-SOP for the annual product review
- 15.G References**

16 Research and Development

16.A General conditions and legal requirements

16.B Development phases and GMP requirements

- 16.B.1 Formulation development
- 16.B.2 Analytical development
- 16.B.3 Manufacturing and testing of stability samples
- 16.B.4 Packaging development
- 16.B.5 Process development
- 16.B.6 Cleaning verification and validation
- 16.B.7 Process optimization:
Basic principles for process validation
- 16.B.8 Up scaling to pilot plant and production scale
- 16.B.9 Handover to other manufacturing sites

16.C Interfaces to GLP and GCP

- 16.C.1 GLP – Good Laboratory Practice
- 16.C.2 GCP – Good Clinical Practice
- 16.C.3 Interfaces between the areas regulated by GMP
and those regulated by GCP

16.D Manufacture and control of clinical samples

- 16.D.1 Prerequisites for the approval of clinical investigations
- 16.D.2 Manufacturing of clinical samples and comparator drugs
- 16.D.3 Packaging and labeling
- 16.D.4 Control and release of investigational medicinal products
- 16.D.5 Storage and shipment of investigational drugs
- 16.D.6 Returns, recalls and destruction of clinical samples

16.E Documentation and recording of changes during development

16.F Development report

16.G Quality by design (QbD)

- 16.G.1 Introduction
- 16.G.2 The Regulatory Framework
- 16.G.3 The New Quality Paradigm
- 16.G.4 Applying Quality by Design
- 16.G.5 Implementing Quality by Design
- 16.G.6 Application Examples
- 16.G.7 Outlook

16.H References

17 Contractors and Suppliers

17.A Contract manufacture

- 17.A.1 Reasons for contract manufacture
- 17.A.2 Procedure for assigning manufacturing contracts
- 17.A.3 Duties of the contract giver
- 17.A.4 Duties of the contract acceptor
- 17.A.5 Contract manufacturer agreement
- 17.A.6 Audits of contract manufacturers
- 17.A.7 SOP for assigning manufacturing contracts
- 17.A.8 Framework contract for contract manufacture and quality control

17.B Contract Analysis

- 17.B.1 Introduction
- 17.B.2 Legal background
- 17.B.3 Selection of an external testing laboratory
- 17.B.4 Liability limitation contract
- 17.B.5 Certificate of Analysis
- 17.B.6 Transfer of the test to the contract laboratory

17.C Suppliers

- 17.C.1 Introduction
- 17.C.2 Definitions
- 17.C.3 Quality systems
- 17.C.4 Records
- 17.C.5 Contracts and quality agreements
- 17.C.6 Supplier review and controls
- 17.C.7 Supplier audits
- 17.C.8 Re-evaluation of Suppliers
- 17.C.9 GMP MANUAL Cross References to Suppliers

17.D References

18 Inspections

18.A Principles

18.B Inspection procedures

- 18.B.1 System-based
- 18.B.2 Product-based
- 18.B.3 Procedure-based
- 18.B.4 Area-based

18.C Inspectors

- 18.C.1 Technical qualification requirements
- 18.C.2 Personal requirements

- 18.D Organization of inspections**
- 18.D.1 Inspection planning
- 18.D.2 Inspection preparation
- 18.D.3 Carrying out the inspections
- 18.D.4 Evaluation and documentation

- 18.E Self-inspection**
- 18.E.1 Purpose of self-inspection
- 18.E.2 Carrying out the self-inspection
- 18.E.3 Self-inspection documentation
- 18.E.4 Errors and remedial action
- 18.E.5 Follow-up activities

- 18.F Inspection of contract manufacturers**
- 18.F.1 Purpose of the inspection of contract manufacturer
- 18.F.2 Carrying out inspections of contract manufacturer
- 18.F.3 Handling of changes and deviations

- 18.G Inspection of suppliers**
- 18.G.1 Purpose of the supplier inspection
- 18.G.2 Carrying out the supplier inspection

- 18.H Questionnaire for preparing GMP-inspections**

- 18.I Inspection of API manufacturers**
- 18.I.1 Preparation of the inspection
- 18.I.2 Type of inspection
- 18.I.3 Inspection questionnaire

- 18.J References**

- 19 Quality Unit**

- 19.A General**
- This chapter will be part of a later update.**

- 19.B The “Qualified Person” according to Directive 2001/83/EC**
- 19.B.1 Introduction
- 19.B.2 Legal background of the European “Qualified Person” regulations
- 19.B.3 Qualification and experience
- 19.B.4 Duties and responsibilities
- 19.B.5 Qualified Person and Pharmaceutical Quality Systems

- 19.C Change Management**
- 19.C.1 Principles of Change Control
- 19.C.2 Boundary Conditions
- 19.C.3 Regulatory aspects
- 19.C.4 Conducting the Change Control Procedure

19.C.5 Evaluating the Change Control System

19.C.6 Documenting the Change Control

19.D Corrective and Preventive Actions (CAPA)

19.D.1 Introduction

19.D.2 Regulatory Background

19.D.3 Definitions

19.D.4 Organizational Integration

19.D.5 Documentation and Tracking

19.D.6 Efficacy and Sustainability

19.D.7 Efficient Implementation

19.D.8 Sample SOP "CAPA System"

19.E References

20 Continual Improvement

20.A Preface

20.B Six Sigma

20.B.1 Definition

20.B.2 What it is / what it does / how it works

20.B.3 Goals/Objectives/Benefits

20.B.4 Implementation

20.B.5 Tools

20.B.6 Variations

20.B.7 Examples

20.C Statistical Process Control (SPC)

20.C.1 Definition

20.C.2 What it is / what it does / how it works

20.C.3 Goals/Objectives/Benefits

20.C.4 Implementation

20.C.5 Tools

20.C.6 Variations

20.C.7 Examples

20.D Process Analytical Technology (PAT)

20.D.1 Definition

20.D.2 The Role of PAT in Pharmaceutical Manufacturing

20.D.3 Regulatory Perspective and Guidances

20.D.4 PAT instrumentation

20.D.5 Application of PAT in a GMP environment

20.D.6 Examples of PAT Applications

20.E References

21 Active and Inactive Ingredients

21.A GMP for Active Pharmaceutical Ingredients (APIs)

- 21.A.1 Introduction
- 21.A.2 Quality management
- 21.A.3 Personnel
- 21.A.4 Buildings and facilities
- 21.A.5 Process equipment
- 21.A.6 Documentation and records
- 21.A.7 Materials management
- 21.A.8 Production and in-process controls
- 21.A.9 Packaging and identification labelling of APIs and intermediates
- 21.A.10 Storage and distribution
- 21.A.11 Laboratory controls
- 21.A.12 Validation
- 21.A.13 Change Control
- 21.A.14 Rejection and re-use of materials
- 21.A.15 Complaints and Recalls
- 21.A.16 Contract manufacturers, including laboratories
- 21.A.17 Agents, brokers, traders, distributors, repackers, and relabellers
- 21.A.18 Specific guidance for APIs manufactured by cell culture/fermentation
- 21.A.19 APIs for use in clinical trials

21.B GMP for APIs – considerations on special topics

- 21.B.1 Materials management
- 21.B.2 Production and maintenance
- 21.B.3 Re-use and recovery of materials
- 21.B.4 Interaction with brokers

21.C Excipients

- 21.C.1 Introduction
- 21.C.2 Regulatory aspects and guidance documents
- 21.C.3 Safety, toxicological, and precedence of use issues
- 21.C.4 Compendial monographs
- 21.C.5 Excipient Master Files and other filings
- 21.C.6 Applicability of ICH guidance to excipients
- 21.C.7 Other aspects critical to the marketing of excipients

21.D References

22	Biologics
23	Medical Devices
23.A	Introduction
23.A.1	Definition
23.A.2	Types of medical devices
23.A.3	Regulatory background
23.A.4	Process approach to a Quality Management System
23.B	Quality Management System (QMS)
23.B.1	Management responsibility
23.B.2	Quality manual
23.B.3	Quality policy
23.B.4	Quality planning
23.B.5	Management review
23.B.6	Audits
23.C	Personnel
23.C.1	General
23.C.2	Training
23.C.3	Health, hygiene, practices, and clothing
23.C.4	Consultants and contractors
23.D	Design control
23.D.1	General
23.D.2	Design planning
23.D.3	Design input
23.D.4	Design output
23.D.5	Design review
23.D.6	Design verification
23.D.7	Design validation / Clinical evaluation
23.D.8	Design transfer
23.D.9	Design changes
23.D.10	Design history file
23.E	Human factors
23.F	Statistical techniques
23.G	Risk management
23.H	Document and record control
23.H.1	Control of documents
23.H.2	Control of records
23.I	Production and process controls
23.I.1	Manufacturing materials
23.I.2	Automated processes

- 23.I.3 Sterile products
- 23.I.4 Changes
- 23.I.5 Material acceptance procedures
- 23.J Identification and traceability**
 - 23.J.1 Identification
 - 23.J.2 Traceability
- 23.K Buildings, facilities and equipment**
 - 23.K.1 Buildings and facilities
 - 23.K.2 Environment
 - 23.K.3 Equipment
- 23.L Validation**
- 23.M Purchasing/supplier control**
 - 23.M.1 Purchase orders
 - 23.M.2 Quality agreements
- 23.N Packaging and labeling**
 - 23.N.1 Packaging
 - 23.N.2 Manufacturer's information
- 23.O Handling, storage, distribution, installation and servicing**
 - 23.O.1 Handling
 - 23.O.2 Storage
 - 23.O.3 Distribution
 - 23.O.4 Installation
 - 23.O.5 Servicing
- 23.P Nonconformance, Corrective Action and Preventive Action**
 - 23.P.1 Definitions
 - 23.P.2 CAPA System
 - 23.P.3 Nonconforming product
 - 23.P.4 Advisory notice, device correction or product recall
- 23.Q Customer complaints**
 - 23.Q.1 Complaint evaluation
 - 23.Q.2 Complaint investigation
- 23.R Combination products**
- 23.S References**

- A** **Empty Register**
- B** **Empty Register**
- C** **EU Directives and Guidelines**
- C.1 **EU GMP Guide: Introduction**
- C.2 **Commission Directive 2003/94/EC**
- C.3 **Commission Directive 91/412/EEC**
- C.4 **Part I**
Basic Requirements for Medicinal Products
- C.4.1 **Chapter 1:**
Pharmaceutical Quality System
- C.4.2 **Chapter 2:**
Personnel
- C.4.3 **Chapter 3:**
Premises and Equipment
- C.4.4 **Chapter 4:**
Documentation
- C.4.5 **Chapter 5:**
Production
- C.4.6 **Chapter 6:**
Quality Control
- C.4.7 **Chapter 7:**
Outsourced Activities
- C.4.8 **Chapter 8:**
Complaints and Product Recall
- C.4.9 **Chapter 9:**
Self Inspection
- C.5 **Part II**
Basic Requirements for Active Substances used as Starting Materials
- C.6.1 **Annex 1**
Manufacture of Sterile Medicinal Products
- C.6.2 **Annex 2:**
Manufacture of Biological active substances and Medicinal Products for Human Use
- C.6.3 **Annex 3**
Manufacture of Radiopharmaceuticals
- C.6.4 **Annex 4**
Manufacture of Veterinary Medicinal Products other than Immunological Veterinary Medicinal Products

- C.6.5 Annex 5
 Manufacture of Immunological Veterinary Medicinal Products**
- C.6.6 Annex 6
 Manufacture of Medicinal Gases**
- C.6.7 Annex 7
 Manufacture of Herbal Medicinal Products**
- C.6.8 Annex 8
 Sampling of Starting and Packaging Materials**
- C.6.9 Annex 9
 Manufacture of Liquids, Creams and Ointments**
- C.6.10 Annex 10
 Manufacture of Pressurised Metered Dose Aerosol Preparations
 for Inhalation**
- C.6.11 Annex 11
 Computerised Systems**
- C.6.12 Annex 12
 Use of Ionising Radiation in the Manufacture of Medicinal
 Products**
- C.6.13 Annex 13
 Investigational Medicinal Products**
- C.6.14 Annex 14
 Manufacture of Medicinal Products Derived from Human Blood
 or Plasma**
- C.6.15 Annex 15
 Qualification and Validation**
- C.6.16 Annex 16
 Certification by a Qualified Person and Batch Release**
- C.6.17 Annex 17
 Parametric Release**
- C.6.18 Annex 18
 Good Manufacturing Practice for Active Pharmaceutical
 Ingredients**
- C.6.19 Annex 19
 Reference and Retention Samples**
- C.7 Glossary**
- C.8 Part III – GMP related documents**
 - C.8.1 Explanatory Notes on the preparation of a Site Master File**
 - C.8.2 Quality Risk Management (ICH Q9)**
 - C.8.3 Pharmaceutical Quality System (ICH Q10)**
 - C.8.4 Internationally harmonised requirements for batch
 certification**

- C.8.5 New Rules on Importing Active Pharmaceutical Ingredients into the European Union**
- C.8.5.1 Importation of Active Substances for Medicinal Products for Human Use Questions and Answers Version 1.0**
- C.9 Note For Guidance on Quality of Water for Pharmaceutical Use**
- C.10 Compilation of Community Procedures on Inspections and Exchange of Information**
- C.10.1 Conduct of Inspections of Pharmaceutical Manufacturers or Importers**
- C.10.2 Outline of a Procedure for Co-Ordinating the Verification of the GMP Status of Manufacturers in Third Countries**
- C.10.3 Guideline on Training and Qualifications of GMP Inspectors**
- C.10.4 Guidance on the Occasions when it is Appropriate for Competent Authorities to Conduct Inspections at the Premises of Manufacturers of Active Substances Used as Starting Materials**
- C.10.5 The Issue and Update of GMP Certificates**
- C.10.6 A Model for Risk Based Planning for Inspections of Pharmaceutical Manufacturers**
- C.10.7 Procedure for dealing with serious GMP non-compliance or voiding/suspension of CEPS thus requiring co-ordinated administrative action**
- C.11 EU Directives on Medical Devices**
- C.11.1 Council Directive of 20 June 1990 on the approximation of the laws of the member states relating to active implantable medical devices (90/385/EEC)**
- C.11.2 Council Directive of 14 June 1993 concerning medical devices (93/42/EEC)**
- C.11.3 Directive of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices (98/79/EC)**
- C.12 Directive 2001/83/EC of the European Parliament and of the Council**
- C.13 Guideline on Real Time Release Testing**

- D USA: CFR and FDA Guidelines**
- D.1 Code of Federal Regulations**
 - D.1.1 21 CFR Part 210
Current Good Manufacturing Practice in Manufacturing,
Processing, Packing, or Holding of Drugs; General**
 - D.1.2 21 CFR Part 211
Current Good Manufacturing Practice for Finished
Pharmaceuticals**
 - D.1.3 21 CFR Part 11
Electronic Records; Electronic Signatures**
 - D.1.4 21 CFR Part 820
Quality System Regulation**
- D.2 Guidance for Industry
Process Validation: General Principles and Practices**
- D.3 Guide to Inspections
of High Purity Water Systems**
- D.4 Guide to Inspections
of Validation of Cleaning Processes**
- D.5 Guide to Inspections
of oral solid dosage forms pre/post approval issues for
development and validation**
- D.6 Guide to Inspections
of Validation Documentation**
- D.7 Guide to Inspections
Computerized Systems in Drug Establishments (2/83)**
- D.8 Guide to Inspections
of Pharmaceutical Quality Control Laboratories**
- D.9 Guidance for Industry
Investigating Out-of-Specification (OOS)
Test Results for Pharmaceutical Production**
- D.10 Guidance for Industry
Sterile Drug Products Produced by Aseptic Processing – Current
Good Manufacturing Practice**
- D.11 Guidance for Industry
PAT – A Framework for Innovative Pharmaceutical
Development, Manufacturing, and Quality Assurance**
- D.12 Guidance for Industry
Part 11, Electronic Records; Electronic Signatures – Scope and
Application**
- D.13 Guidance for Industry
Incorporation of Physical-Chemical Identifiers into Solid Oral
Dosage Form Drug Products for Anticounterfeiting**

- D.14 **Guidance for Industry
Quality Systems Approach to Pharmaceutical CGMP
Regulations**
- D.15 **Guidance for Industry
cGMP for Phase 1 Investigational Drugs**
- D.16 **Federal Food, Drug, and Cosmetic Act (FD&C Act)**
- D.17 **Pre-Approval Inspections**

E ICH-Guidelines

- E.1.A **ICH Q1A(R2):
Stability Testing of New Drug Substances and Products**
- E.1.B **ICH Q1B:
Stability Testing: Photostability Testing of New Drug
Substances and Products**
- E.1.C **ICH Q1C:
Stability Testing for New Dosage Forms**
- E.1.D **ICH Q1D:
Bracketing and Matrixing Designs for Stability Testing of New
Drug Substances and Products**
- E.1.E **ICH Q1E:
Evaluation of Stability Data**
- E.2 **ICH Q2(R1):
Validation of Analytical Procedures:
Text and Methodology**
- E.3.A **ICH Q3A(R2):
Impurities in New Drug Substances**
- E.3.B **ICH Q3B(R2):
Impurities in New Drug Products**
- E.3.C **ICH Q3C(R5):
Impurities: Guideline for Residual Solvents**
- E.4 **ICH Q4:
Pharmacopoeias**
- E.4.A **ICH Q4A:
Pharmacopoeial Harmonisation**
- E.4.B **ICH Q4B:
Evaluation and Recommendation of Pharmacopoeial Texts for
Use in the ICH Regions**
- E.4.B.1 **ICH Q4B Annex 1:
Evaluation and Recommendation
of Pharmacopoeial Texts for Use in the ICH Regions
on Residue on Ignition/Sulphated Ash –
General Chapter**

- E.4.B.2 ICH Q4B Annex 2:
Evaluation and Recommendation
of Pharmacopoeial Texts for Use in the ICH Regions
on Test for Extractable Volume of Parenteral Preparations –
General Chapter**
- E.4.B.3 ICH Q4B Annex 3:
Evaluation and Recommendation
of Pharmacopoeial Texts for Use in the ICH Regions
on Test for Particulate Contamination: Sub-Visible Particles –
General Chapter**
- E.4.B.4.1 ICH Q4B Annex 4A:
Evaluation and Recommendation
of Pharmacopoeial Texts for Use in the ICH Regions
Microbiological Examination
of Non-Sterile Products:
Microbial Enumerations Tests –
General Chapter**
- E.4.B.4.2 ICH Q4B Annex 4B :
Evaluation and Recommendation of Pharmacopoeial Texts
for Use in the ICH Regions on
Microbiological Examination of Non-Sterile Products:
Test for Specified Micro-Organisms – General Chapter**
- E.4.B.4.3 ICH Q4B Annex 4C:
Evaluation and Recommendation
of Pharmacopoeial Texts for Use in the ICH Regions
on Microbiological Examination
of Non-Sterile Products:
Acceptance Criteria For Pharmaceutical Preparations and
Substances for Pharmaceutical Use –General Chapter**
- E.4.B.5 ICH Q4B Annex 5:
Evaluation and Recommendation
of Pharmacopoeial Texts for Use in the ICH Regions
on Disintegration Test – General Chapter**
- E.4.B.6 ICH Q4B Annex 6:
Evaluation and Recommendation
of Pharmacopoeial Texts for Use in the ICH Regions
on Uniformity of Dosage Units –General Chapter**
- E.4.B.7 ICH Q4B Annex 7:
Evaluation and Recommendation
of Pharmacopoeial Texts for Use in the ICH Regions
on Dissolution Test – General Chapter**
- E.4.B.8 ICH Q4B Annex 8:
Evaluation and Recommendation
of Pharmacopoeial Texts for Use in the ICH Regions
on Sterility Test – General Chapter**
- E.4.B.9 ICH Q4B Annex 9:
Evaluation and Recommendation
of Pharmacopoeial Texts for Use in the ICH Regions
on Tablet Friability – General Chapter**

- E.4.B.10 ICH Q4B Annex 10:
Evaluation and Recommendation
of Pharmacopoeial Texts for Use in the ICH Regions
on Polyacrylamide Gel Electrophoresis – General Chapter**
- E.5.A ICH Q5A(R1):
Viral Safety Evaluation of Biotechnology Products Derived from
Cell Lines of Human or Animal Origin**
- E.5.B ICH Q5B:
Quality of Biotechnological Products: Analysis of the Expression
Construct in Cells Used for Production of R-DNA Derived
Protein Products**
- E.5.C ICH Q5C:
Quality of Biotechnological Products: Stability Testing of
Biotechnological/Biological Products**
- E.5.D ICH Q5D:
Derivation and Characterisation of Cell Substrates used for
Production of Biotechnological/Biological Products**
- E.5.E ICH Q5E:
Comparability of Biotechnological/Biological Products Subject
to Changes in their Manufacturing Process**
- E.6.A ICH Q6A:
Specifications: Test Procedures and Acceptance Criteria for New
Drug Substances and New Drug Products: Chemical Substances**
- E.6.B ICH Q6B:
Specifications: Test Procedures and Acceptance Criteria for
Biotechnological/Biological Products**
- E.7 ICH Q7:
Good Manufacturing Practice Guide for Active Pharmaceutical
Ingredients
combined with
GMPs for APIs: „How to do“ Document
by Cefic/APIIC
Interpretation of the ICH Q7 Guide**
 - E.7.1 Chapter 1:
Introduction**
 - E.7.2 Chapter 2:
Quality Management**
 - E.7.3 Chapter 3:
Personnel**
 - E.7.4 Chapter 4:
Buildings and Facilities**
 - E.7.5 Chapter 5
Process Equipment**
 - E.7.6 Chapter 6:
Documentation and Records**

- E.7.7 Chapter 7:
Materials Management**
- E.7.8 Chapter 8:
Production and In-Process Controls**
- E.7.9 Chapter 9:
Packaging and Identification Labelling of APIs and
Intermediates**
- E.7.10 Chapter 10:
Storage and Distribution**
- E.7.11 Chapter 11:
Laboratory Controls**
- E.7.12 Chapter 12:
Validation**
- E.7.13 Chapter 13:
Change Control**
- E.7.14 Chapter 14:
Rejection and Re-use of Materials**
- E.7.15 Chapter 15:
Complaints and Recalls**
- E.7.16 Chapter 16:
Contract Manufacturers
(including Laboratories)**
- E.7.17 Chapter 17:
Agents, Brokers, Traders, Distributors, Repackers, and
Relabellers**
- E.7.18 Chapter 18:
Specific Guidance for APIs Manufactured by Cell Culture/
Fermentation**
- E.7.19 Chapter 19:
APIs for Use in Clinical Trials**
- E.7.20 Chapter 20:
Glossary**
- E.8 ICH Q8 (R2):
Pharmaceutical Development**
- E.9 ICH Q9:
Quality Risk Management**
- E.10 ICH Q10:
Pharmaceutical Quality System**
- E.10.1 Quality Implementation Working Group
on Q8, Q9 and Q10
Questions & Answers**

- F PIC/S Guidelines**
- F.1 PIC/S PI 006-3:
Recommendations on
Validation Master Plan
Installation and Operational Qualification
Non-Sterile Process Validation
Cleaning Validation**
 - F.2 PIC/S PI 007-6:
Recommendation on the
Validation of Aseptic Processes**
 - F.3 PIC/S PI 011-3:
PIC/S Guidance
Good Practices for
Computerised Systems in Regulated “GXP” Environments**
 - F.4 PIC/S PI 023-2:
Aide-mémoire
Inspection of Pharmaceutical Quality Control Laboratories**
 - F.4.1 Annex to PIC/S PI 023-1
Aide-Memoire
for Inspections of Pharmaceutical Quality Control Laboratories**
 - F.5 PIC/S PE 008-4:
Explanatory notes for pharmaceutical manufacturers on the
preparation of a Site Master File**
 - F.6 PIC/S PI 009-3:
Aide-mémoire
Inspection of Utilities**
 - F.7 PIC/S PI 028-1:
Aide-mémoire
GMP Inspection Related to Packaging**
 - F.8 PIC/S PI 032-2:
Recommendation
GMP Annex 1 Revision 2008,
Interpretation of Most Important Changes for the Manufacture
of Sterile Medicinal Products**
 - F.9 PIC/S PE 009-9:
Guide to Good Manufacturing Practice for Medicinal Products
– Intro**
 - F.10 PIC/S PE 009-9:
Guide to Good Manufacturing Practice for Medicinal Products
– Part I**
 - F.11 PIC/S PE 009-9:
Guide to Good Manufacturing Practice for Medicinal Products
– Part II**
 - F.12 PIC/S PE 009-9:
Guide to Good Manufacturing Practice for Medicinal Products
– Annexes**

G GMP of other Regions

G.1 WHO Guidelines

G.1.1 Quality assurance of pharmaceuticals

G.1.1.1 1. WHO good manufacturing practices: main principles for pharmaceutical products

G.1.1.2 2. WHO good manufacturing practices: starting materials

G.1.1.3 3. WHO good manufacturing practices: specific pharmaceutical products

G.1.1.4 4. Inspection

G.1.1.5 5. Hazard and risk analysis in pharmaceutical products

G.1.1.6 6. Sampling operations

**G.1.2 WHO TRS 908 (2003), Annex 9:
Guide to good storage practices for pharmaceuticals**

**G.1.3 WHO TRS 957 (2010), Annex 5:
Good distribution practices for pharmaceutical products**

**G.1.4 WHO TRS 961 (2011), Annex 9:
Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products)**

G.2 Canadian Regulations

**G.2.1 Good Manufacturing Practices (GMP) Guidelines –
2009 Edition, Version 2 (GUI-0001)**

**G.2.2 Canada:
Good Manufacturing Practices (GMP) Guidelines – Annexes**

**G.2.2.1 Annex 1
to the Current Edition of the Good Manufacturing Practices
Guidelines – Selected Category IV Monograph Drugs
(GUI-0066)**

**G.2.2.2 Annex 2
to the Current Edition of the Good Manufacturing Practices
Guidelines – Schedule D Drugs, (Biological Drugs) (GUI-0027)**

**G.2.2.3 Annex 3
to the Current Edition of the Good Manufacturing Practices
Guidelines – Schedule C Drugs (GUI-0026)**

**G.2.2.4 Annex 4
to the Current Edition of the Good Manufacturing Practices
Guidelines – Veterinary Drugs (GUI-0012)**

**G.2.2.5 Annex 5
to the Current Edition of the Good Manufacturing Practices
Guidelines – Positron Emitting Radiopharmaceuticals (PER's)
(GUI-0071)**

- G.2.2.6 **Annex 13
to the Current Edition of the Good Manufacturing Practices
Guidelines – Drugs Used in Clinical Trials (GUI-0036)**
- G.2.2.7 **Annex 14
to the Current Edition of the Good Manufacturing Practices
Guidelines – Schedule D Drugs, Human Blood and Blood
Components (GUI-0032)**
- G.3 **Japanese Regulations**
 - G.3.1 **MHW Ministerial Ordinance No. 2,1961:
Regulations for Buildings and Facilities of Pharmacies, etc.**
 - G.3.2 **MHLW Ministerial Ordinance No. 136,2004 :
Standards for Quality Assurance for Drugs, Quasi-drugs,
Cosmetics and Medical Devices**
 - G.3.3 **MHLW Ministerial Ordinance No. 179, 2004:
Standards for Manufacturing Control and Quality Control for
Drugs and Quasi-drugs**
- G.4 **Chinese Regulations**
 - G.4.1 **China
Good Manufacturing Practice for Drugs (2010 Revision)**
 - G.4.2 **China:
Good Manufacturing Practice (2010 revision)
Annex 1 to Annex 5
Technical Reviewed by ISPE**
 - G.4.2.1 **Annex 1:
Sterile Medicinal Products**
 - G.4.2.2 **Annex 2:
Active Substances Used As Starting Materials**
 - G.4.2.3 **Annex 3:
Biological Medicinal**
 - G.4.2.4 **Annex 4:
Blood Products**
 - G.4.2.5 **Annex 5:
Chinese Medicine Preparations**
- H **Information**
 - H.1 **GMP Abbreviations**
 - H.2 **GMP Glossary**
 - H.3 **Adresses**
 - H.4 **References**